A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

While teclistamab looks on course to be the first BCMA-targeting bispecific antibody to reach the market, Pfizer is hot on J&J's heels with its BCMAxCD3 drug elranatamab and reported phase 2 data ...

Multiple myeloma accounts for about 10% of all hematological ... followed in 2022. Both target BCMA. Now, in the last 12 months, six phase III trials have produced compelling data for the survival ...

Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...